Last C$1.26 CAD
Change Today 0.00 / 0.00%
Volume 13.2K
AEZ On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 4:10 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

aeterna zentaris inc (AEZ) Snapshot

Open
C$1.26
Previous Close
C$1.26
Day High
C$1.27
Day Low
C$1.25
52 Week High
09/5/13 - C$1.81
52 Week Low
11/20/13 - C$1.04
Market Cap
71.2M
Average Volume 10 Days
64.9K
EPS TTM
C$0.14
Shares Outstanding
56.5M
EX-Date
--
P/E TM
8.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for AETERNA ZENTARIS INC (AEZ)

Related News

No related news articles were found.

aeterna zentaris inc (AEZ) Related Businessweek News

No Related Businessweek News Found

aeterna zentaris inc (AEZ) Details

Aeterna Zentaris Inc., a specialty biopharmaceutical company, is focused on developing and commercializing novel treatments in oncology and endocrinology. The company’s product pipeline includes MACRILEN, for which a New Drug Application is under review by the FDA as an oral product used for evaluating adult growth hormone deficiency. MACRILEN is also investigated in a Phase 2A clinical trial to treat cancer-induced cachexia. Its product pipeline also comprises zoptarelin doxorubicin, which is in the ZoptEC (zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent, or metastatic endometrial cancer. In addition, the company’s preclinical product candidates in oncology include AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136; and disorazol Z product candidates, such as AEZS-137 and AEZS-138. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.

Founded in 1991

aeterna zentaris inc (AEZ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $328.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $331.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $122.0K
Compensation as of Fiscal Year 2013.

aeterna zentaris inc (AEZ) Key Developments

Aeterna Zentaris Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 11:30 AM

Aeterna Zentaris Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 11:30 AM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.

Aeterna Zentaris Inc. Announces Board Changes

Aeterna Zentaris Inc. announced that its annual meeting of shareholders held on May 9, 2014, its board of directors has appointed current President and CEO, David Dodd, as Chairman of the board, a decision that is in keeping with Aeterna Zentaris' new strategy of transitioning from a research and development into a commercial company. The board believes that with both roles being assumed by David Dodd, the decision-making process of the leadership will be more efficient, which should also accelerate the attainment of the company's objective of becoming a commercial entity. In order to ensure that the board of directors will continue to act independently from management, Juergen Ernst, former Chairman of the board and an independent director, will assume the role of Lead Director.

Aeterna Zentaris Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Aeterna Zentaris Inc. announced consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, Revenue was nil compared to $6.1 million for the same period in 2013 which had resulted predominantly from the non-recurring, accelerated recognition of remaining unamortized deferred revenue related to an upfront payment received from a licensing partner following the termination of related R&D activities. Loss from operations was $8,195,000 against $1,163,000 a year ago. Net finance income was $3.89 million, compared to $2.17 million for the same quarter ended March 31, 2013. Net loss from continuing operations was $4,304,000 or $0.08 per basic and diluted share against net profit from continuing operations of $1,003,000 or $0.04 per basic and diluted share a year ago. Net loss was $4.4 million, or $0.08 per basic and diluted share, compared to $1.9 million, or $0.07 per basic and diluted share, for the same period in 2013. This decrease in net income is due largely to lower revenues, higher operating expenses and higher net loss from discontinued operations, partially offset by higher comparative net finance income.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEZ:CN C$1.26 CAD 0.00

AEZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEZ.
View Industry Companies
 

Industry Analysis

AEZ

Industry Average

Valuation AEZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 566.4x
Price/Book 4.0x
Price/Cash Flow 114.9x
TEV/Sales 177.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETERNA ZENTARIS INC, please visit www.aezsinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.